Prediction of Acute Mountain Sickness using a Blood-Based Test
Annual rept. 20 Dec 2011-19 Dec 2012
COLORADO UNIV AURORA CO
Pagination or Media Count:
In the second year we have worked on obtaining IRB approval for Phase II, the validation field work component of the study. As of December 19th 2012 the University of Texas Southwestern Medical School as well as the University of Colorado School of Medicine have approved the protocol. The Human Research Protection Office of the Department of Defense completed initial review and is expected to approve the final protocol in January 2013. The data collected during Phase I, which was designed to test the concept that an RNA-based gene signature could be used to predict individuals who develop acute mountain sickness and those who do not get sick were very successful. The findings confirm our preliminary analyses and showed that we can successfully predict 9 out of 10 cases of acute mountain sickness and of AMS resistance. In other words, we correctly determined the response in more than 90 of the subjects tested. Phase II of the study is to validate these results in a smaller cohort. As soon as HRPO approval will be final, we will start planning this phase, which will take place in July 2013.
- Medicine and Medical Research